UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection

Antiviral research, 2024-09, Vol.229, p.105960, Article 105960

2024

Volltextzugriff (PDF)

Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice

Virology (New York, N.Y.), 2024-10, Vol.598, p.110194, Article 110194

2024

Volltextzugriff (PDF)

Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy

The New England journal of medicine, 2022-04, Vol.386 (17), p.1615-1626

2022

Volltextzugriff (PDF)

Viral N 6 -methyladenosine upregulates replication and pathogenesis of human respiratory syncytial virus

Nature communications, 2019-10, Vol.10 (1), p.4595-18

2019

Volltextzugriff (PDF)

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

The Journal of infectious diseases, 2017-12, Vol.216 (11), p.1362-1370

2017

Volltextzugriff (PDF)

Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation

Science (American Association for the Advancement of Science), 2024-09, Vol.385 (6716), p.1484-1491

2024

Volltextzugriff (PDF)

Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus

Frontiers in immunology, 2024-06, Vol.15, p.1376395

2024

Volltextzugriff (PDF)

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.e637-e646

2024

Volltextzugriff (PDF)

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Clinical infectious diseases, 2024-05, Vol.78 (5), p.1360-1368

2024

Volltextzugriff (PDF)

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Antimicrobial agents and chemotherapy, 2016-01, Vol.60 (1), p.6-13

2016

Volltextzugriff (PDF)

Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model

Nature communications, 2018-05, Vol.9 (1), p.1904-10, Article 1904

2018

Volltextzugriff (PDF)

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?

The Lancet infectious diseases, 2016-08, Vol.16 (8), p.e153-e163

2016

Volltextzugriff (PDF)

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.e647-e656

2024

Volltextzugriff (PDF)

Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants

Vaccine, 2020-01, Vol.38 (2), p.251-257

2020

Volltextzugriff (PDF)

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

The Journal of infectious diseases, 2017-01, Vol.215 (1), p.24-33

2017

Volltextzugriff (PDF)

Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children

The Journal of infectious diseases, 2020-02, Vol.221 (4), p.534-543

2020

Volltextzugriff (PDF)

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

The Journal of infectious diseases, 2024-07, Vol.230 (1), p.e102-e110

2024

Volltextzugriff (PDF)

Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective

Journal of virology, 2017-05, Vol.91 (10)

2017

Volltextzugriff (PDF)

VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice

Vaccine, 2024-05, Vol.42 (15), p.3474-3485

2024

Volltextzugriff (PDF)

The CD4 T cell response to respiratory syncytial virus infection

Immunologic research, 2014-08, Vol.59 (1-3), p.109-117

2014

Volltextzugriff (PDF)

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Immunity (Cambridge, Mass.), 2021-04, Vol.54 (4), p.769-780.e6

2021

Volltextzugriff (PDF)

RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection

Nature communications, 2015-12, Vol.6 (1), p.10224, Article 10224

2015

Volltextzugriff (PDF)

Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study

The Lancet infectious diseases, 2024-09, Vol.24 (9), p.1015-1024

2024

Volltextzugriff (PDF)

Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure

Frontiers in immunology, 2024-04, Vol.15, p.1377374-1377374

2024

Volltextzugriff (PDF)

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study

The Journal of infectious diseases, 2024-08, Vol.230 (2), p.e353-e362

2024

Volltextzugriff (PDF)

1 – 25 von 1.862

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.825)

Publikationsform

Artikel
(1.861)
Buchkapitel
(1)

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.740)
Life Sciences & Biomedicine
(1.625)
Humans
(1.386)
Respiratory Syncytial Virus
(1.270)
Male
(1.081)
Immunology
(953)
Animals
(775)
Infant
(715)
Respiratory Syncytial Virus Infections - Immunology
(715)
Infectious Diseases
(622)
Biological And Medical Sciences
(589)
Mice
(562)
Microbiology
(560)
Respiratory Syncytial Viruses - Immunology
(524)
Mice, Inbred Balb C
(501)
Viruses
(471)
Virology
(470)
Child, Preschool
(439)
Infections
(435)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection

Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice

Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy

Viral N 6 -methyladenosine upregulates replication and pathogenesis of human respiratory syncytial virus

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation

Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective

VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice

The CD4 T cell response to respiratory syncytial virus infection

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection

Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study

Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study

Aktive Filter

Suchergebnisse filtern